Facebook Pixel "India is now working on the target of ending TB by 2025" | BioSpectrum Asia – business – Lesen Sie diese Geschichte auf Magzter.com

Versuchen GOLD - Frei

"India is now working on the target of ending TB by 2025"

BioSpectrum Asia

|

BioSpectrum Asia April 2023

Noting the declining number of Tuberculosis (TB) patients, India resolved to eliminate TB by 2025 as against the global target of 2030. 

"India is now working on the target of ending TB by 2025"

Referring to the capacity and health infrastructure enhancement during the pandemic, the Prime Minister of India, Narendra Modi underlined the high use of 5Ts namely Trace, Test, Track, Treat and Technology, in the fight against the disease.

Addressing the One World TB Summit in Varanasi (India) held on the occasion of World Tuberculosis Day on March 24, the Prime Minister said that the commitment and determination with which India dedicated itself to tackling TB after 2014 is unprecedented. India’s efforts are important, as this is a new model for the global war on TB. Elaborating on a multi-pronged approach against TB in the last nine years, he listed out many measures such as people’s participation, enhancing nutrition, treatment innovation, tech integration and wellness and prevention such as Fit India, Yoga, and Khelo India type of interventions.

Regarding people’s participation, the Prime Minister talked about the Ni-kshay Mitra Campaign in helping TB patients. He informed that about 10 lakh TB patients have been adopted by citizens and even children aged 10-12 years have came forward. Financial help to the TB patient under the programme has reached up to Rs 1000 crore. He termed the movement ‘inspirational’ and expressed happiness that even Pravasi Indians are participating in this.

WEITERE GESCHICHTEN VON BioSpectrum Asia

BioSpectrum Asia

How FemTech Spurt in APAC is Redefining Healthcare

Despite representing half the global population, women's health has historically received only a fraction of healthcare innovation and investment.

time to read

4 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

China's Colossal Ageing Population and Low Birth Rate Challenge

China's recent policy initiatives pertaining to long-term care insurance, maternity insurance expansion, and primary healthcare reform reflect a coordinated attempt to address deep structural demographic challenges—most notably 'rapid population ageing' and declining birth rates.

time to read

2 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

"We need to prioritise research as several common AYA cancers are significantly under-studied in Asian populations"

At the SingHealth Presidents' Scientific and Partners in Social-care (SPSOC) Conference, Assistant Professor Eileen Poon, Senior Consultant in Medical Oncology at the National Cancer Centre Singapore (NCCS) delivered an enlightening presentation.

time to read

7 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

Shimadzu Scientific Instruments opens laboratory in San Francisco Bay Area

Shimadzu Scientific Instruments (SSI) has opened its new research and development (R&D) facility in South San Francisco, California, US.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

NTU and NHG Health partner to advance healthcare education in Singapore

NHG Health's inaugural E3 (Educate, Elevate, Evolve) conference, held recently, was marked by a new partnership with Nanyang Technological University (NTU) Singapore, signalling a significant step in advancing healthcare education through interdisciplinary collaboration.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

"Building a lean team with deep operational expertise increases likelihood of success in rare disease drug development"

More than 300 million people worldwide are impacted by over 10,000 rare diseases, i.e. more than cancer and AIDS combined.

time to read

5 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

Qiagen expands into bloodstream infection syndromic testing with new rapid QIAstat-Dx panel

Qiagen N.V. has announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

Royalty Pharma on-boards Kenneth Sun as Senior Vice President and Head of Asia

US-based Royalty Pharma ple has announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

Waters launches omniDAWN Multi-Angle Light Scattering (MALS) Photometer

US-based Waters Corporation has announced the launch of the Waters omniDAWN Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

South Korea's Cell and Gene Therapy Surge

South Korea's cell and gene therapy (CGT) landscape is highly dynamic, as observed from regulatory approvals, clinical development, and manufacturing activity.

time to read

5 mins

BioSpectrum Asia May 2026

Translate

Share

-
+

Change font size